These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 18165811)

  • 21. Benefits of preserving residual renal function in peritoneal dialysis.
    Marrón B; Remón C; Pérez-Fontán M; Quirós P; Ortíz A
    Kidney Int Suppl; 2008 Apr; (108):S42-51. PubMed ID: 18379546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tidal automated peritoneal dialysis preserves residual renal function better than non tidal automated peritoneal dialysis.
    Adachi Y; Nishio A; Ikegami T
    Adv Perit Dial; 2007; 23():98-101. PubMed ID: 17886612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative study of enalapril vs. losartan on residual renal function preservation in automated peritoneal dialysis. A randomized controlled study.
    Reyes-Marín FA; Calzada C; Ballesteros A; Amato D
    Rev Invest Clin; 2012; 64(4):315-21. PubMed ID: 23227581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The importance of residual renal function in peritoneal dialysis patients.
    Diaz-Buxo JA; White SA; Himmele R
    Adv Perit Dial; 2013; 29():19-24. PubMed ID: 24344485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Maintaining residual renal function in patients on dialysis].
    Ryckelynck JP; Goffin É; Verger C;
    Nephrol Ther; 2013 Nov; 9(6):403-7. PubMed ID: 23768756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic evaluation of neutral-pH, low-glucose degradation product peritoneal dialysis solutions compared with standard solutions: a secondary analysis of the balANZ Trial.
    Howard K; Hayes A; Cho Y; Cass A; Clarke M; Johnson DW
    Am J Kidney Dis; 2015 May; 65(5):773-9. PubMed ID: 25746151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does the use of neutral pH, low glucose degradation product peritoneal dialysis fluids lead to better patient outcomes?
    Cho Y; Johnson DW
    Curr Opin Nephrol Hypertens; 2014 Mar; 23(2):192-7. PubMed ID: 24378773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biocompatible peritoneal dialysis solutions: many questions but few answers.
    Blake PG; Jain AK; Yohanna S
    Kidney Int; 2013 Nov; 84(5):864-6. PubMed ID: 24172730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Residual renal function: considerations on its importance and preservation in dialysis patients.
    Chandna SM; Farrington K
    Semin Dial; 2004; 17(3):196-201. PubMed ID: 15144545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Independent effects of residual renal function and dialysis adequacy on nutritional status and patient outcome in continuous ambulatory peritoneal dialysis.
    Szeto CC; Lai KN; Wong TY; Law MC; Leung CB; Yu AW; Li PK
    Am J Kidney Dis; 1999 Dec; 34(6):1056-64. PubMed ID: 10585315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Residual renal function in children treated with continuous ambulatory peritoneal dialysis or automated peritoneal dialysis--a preliminary study.
    Roszkowska-Blaim M; Skrzypczyk P; Drozdz D; Pietrzyk JA
    Adv Perit Dial; 2009; 25():103-9. PubMed ID: 19886329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of neutral-pH peritoneal dialysates with reduced glucose degradation products on clinical outcomes in peritoneal dialysis patients.
    Cho Y; Johnson DW; Badve SV; Craig JC; Strippoli GF; Wiggins KJ
    Kidney Int; 2013 Nov; 84(5):969-79. PubMed ID: 23698236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A case study on peritoneal dialysis with biocompatible peritoneal dialysis fluid: increase in submesothelial compact zone thickness but not vessel density.
    Tonar Z; Opatrná S; Krízková V; Kocová J; Boudová L; Hes O; Treska AV
    Ther Apher Dial; 2010 Aug; 14(4):438-41. PubMed ID: 20649768
    [No Abstract]   [Full Text] [Related]  

  • 34. [Adequate peritoneal dialysis--new guidelines?].
    Lilaj T
    Wien Klin Wochenschr; 2005; 117 Suppl 6():83-8. PubMed ID: 16437338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of angiotensin converting enzyme inhibitors on potassium homeostasis in dialysis patients with and without residual renal function.
    Garthwaite E; Bhandari S
    Artif Organs; 2009 Aug; 33(8):641-7. PubMed ID: 19624582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The biocompatibility of neutral pH, low-GDP peritoneal dialysis solutions: benefit at bench, bedside, or both?
    Perl J; Nessim SJ; Bargman JM
    Kidney Int; 2011 Apr; 79(8):814-24. PubMed ID: 21248712
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of automated peritoneal dialysis on residual daily urinary volume in children.
    Fischbach M; Terzic J; Menouer S; Soulami K; Dangelser C; Helmstetter A; Gehant F
    Adv Perit Dial; 2001; 17():269-73. PubMed ID: 11510291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utility of cystatin C-derived equations for evaluation of residual renal function in peritoneal dialysis patients.
    Ahmadi F; Rahmani F; Lessan-Pezeshki M; Azmandian J
    Ren Fail; 2015 Feb; 37(1):50-6. PubMed ID: 25268834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. We Use Bioincompatible Peritoneal Dialysis Solutions.
    Troidle L; Hansson J; Juergensen P; Finkelstein FO
    Semin Dial; 2016 Jul; 29(4):263-4. PubMed ID: 27061506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Noninferiority of biocompatible solutions in peritoneal dialysis cannot be maintained.
    García López FJ; del Peso G; Bajo Rubio MA
    Kidney Int; 2008 Oct; 74(7):963; author reply 963. PubMed ID: 18794822
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.